Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer

Trial Profile

Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Veliparib (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 05 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 dec 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top